Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis Accessibility StatementSkip Navigation In the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16 In key secondary endpoints, 39% of patients achieved a high bar of near-complete skin clearance (EASI-90) and ...

2026 年 3 月 16 日 证券研究报告 行业周报 | 行业评级： | | | --- | --- | | 报告期：2026.3.2-2026.3.15 | | | 投资评级 | 看好 | | 评级变动 | 维持评级 | 分析师： 分析师 胡晨曦 huchenxi@gwgsc.com 执业证书编号：S0200518090001 联系电话：010-68085205 分析师 魏钰琪 weiyuqi@gwgsc.com 执业证书编号：S0200525060001 联系电话：010-68099389 公司地址：北京市丰台区凤凰嘴街 2 号院 1 号楼中国长城资产大厦 16 层 医药生物行业双周报 2026 年第 5 期总第 154 期 年报密集披露期已至，国内政策端持续释放积极信号 行业回顾 本报告期医药生物行业指数跌幅为 2.99%，在申万 31 个一级行业中 位居第 14，跑输沪深 300 指数（-0.88%）。从子行业来看，医疗耗 材、体外诊断涨幅居前，涨幅分别为 1.42%、0.93%；医疗设备、医 疗研发外包跌幅居前，跌幅分别为 6.57%、6.54%。 行业走势： 估值方面，截至 2026 年 3 月 ...

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The report highlights that the domestic policy environment is continuously releasing positive signals, with the 2026 government work report explicitly listing biomedicine as a "new pillar industry" [6][25] - The report indicates that the pharmaceutical and biotechnology industry index declined by 2.99%, underperforming the CSI 300 index, with medical consumables and in vitro diagnostics showing positive growth [5][15] - The report emphasizes the importance of focusing on "independent innovation" and "policy benefits" as the main investment themes in the pharmaceutical and biotechnology sector [7] Industry Review - The pharmaceutical and biotechnology industry index experienced a decline of 2.99%, ranking 14th among 31 primary industries, and underperformed the CSI 300 index, which declined by 0.88% [5][15] - The valuation of the pharmaceutical and biotechnology industry as of March 13, 2026, is 30.34x (TTM overall method, excluding negative values), down from 31.06x in the previous period, indicating a downward trend [20] - Among the sub-industries, the top three in terms of PE (TTM overall method, excluding negative values) are vaccines (54.84x), hospitals (41.28x), and medical consumables (39.52x), while the lowest is pharmaceutical circulation (14.66x) [20] Important Industry News - The 2026 government work report has been released, emphasizing biomedicine as a "new pillar industry" and proposing to further expand pilot programs in biotechnology and accelerate the development of innovative drugs and medical devices [6][25] - The "14th Five-Year Plan" outlines multiple references to the pharmaceutical industry, reinforcing support for innovative drugs and related sectors [25][26] - Notable approvals include the global first cAMP biased GLP-1 receptor agonist "Elnoglutide Injection" by Hangzhou Xianweida Biotech and a $30 billion investment by Eli Lilly in China [6][33][42] Investment Recommendations - The report suggests focusing on high-quality pharmaceutical assets with differentiated innovation capabilities and sustainable potential, particularly those benefiting from the high-quality development of innovative drugs and supportive policies [7] - It is recommended to pay attention to innovative drug companies with strong clinical advancement capabilities and global cooperation potential, as their valuation systems are expected to upgrade from single product logic to platform logic [7]

Group 1 - Eli Lilly and Company plans to invest $3 billion in China over the next decade to develop production capacity for its experimental type-2 diabetes and obesity treatment, orforglipron [1] - The company submitted a marketing application for orforglipron to China's drug regulator at the end of 2025 and aims to establish a localized manufacturing and supply system for oral solid dosage forms [1] - Eli Lilly is part of a trend among Western healthcare firms investing in manufacturing in China, following companies like Haleon, while others like Bristol Myers Squibb are divesting from the region [2] Group 2 - Eli Lilly develops, manufactures, discovers, and sells pharmaceutical products across various therapeutic areas, including oncology, diabetes, immunology, and neuroscience [3]

证券研究报告 | 2026年03月15日 美股市场速览 弱于大市 资金向半导体、硬件、能源集中 价格走势：整体下跌，能源与半导体上涨 本周，标普 500 指数-1.6%（上周-2.0%），纳斯达克综指-1.3%（上周-1.2%）。 风格：大盘价值（罗素 1000 价值-1.5%）≈小盘成长（罗素 2000 成长-1.5%） ＞大盘成长（罗素 1000 成长-2.0%）＞小盘价值（罗素 2000 价值-2.1%）。 资金流向：整体小幅流出，集中流向半导体与硬件 本周，标普 500 成分股估算资金流（涨跌额 x 成交量）为-27.1（亿美元， 下同），上周为-99.4，近 4 周为-114.5，近 13 周为-248.3。 4 个行业资金流入，20 个行业资金流出。资金流入的主要有：半导体产品与 设备（+30.8）、技术硬件与设备（+29.7）、能源（+4.1）、材料（+1.4）； 资金流出的主要有：软件与服务（-17.5）、综合金融（-12.5）、资本品（-7.8）、 零售业（-7.6）、媒体与娱乐（-6.7）。 盈利预测：整体稳步上修，能源上修较快 本周，标普 500 成分股动态未来 12 个月 EPS 预期 ...

Core Viewpoint - The Chinese weight loss drug market is rapidly evolving from a two-player competition between foreign companies to a multi-player landscape that includes local innovations and subsequent entrants [2] Group 1: Market Dynamics - The approval and market entry of multiple GLP-1 drugs in China, including Wegovy and Mounjaro, indicate a shift towards a competitive environment with various players [2][3] - The first tier of products includes established players like Novo Nordisk and Eli Lilly, which have proven market capabilities and are targeting self-paying consumers in China [3] - The second tier consists of local innovative drugs like Innovent's Ma Shidu and Senwa's Enoglutide, which aim to differentiate themselves through efficacy and commercialization speed [5] Group 2: Competitive Landscape - The influx of new drugs leads to increased competition for doctors, patients, and distribution channels, creating a challenging environment for new entrants [9] - Upcoming oral GLP-1 drugs, such as Eli Lilly's orforglipron, could change the competitive dynamics by lowering barriers to use and shifting focus to convenience and cost [7] - Multi-target products are raising the efficacy standards, with candidates like UBT251 showing significant weight loss results, indicating a push for better performance in the market [7] Group 3: Future Outlook - The market is expected to favor products that demonstrate clear efficacy, convenient administration methods, competitive pricing, and additional metabolic benefits [11] - Many projects may struggle to reach the market due to the crowded landscape, with only a few types of products likely to survive [11][12] - The window for new entrants is narrowing as the market becomes increasingly saturated with established and upcoming competitors [12]

The U.S. stock market faced a volatile session on Friday, March 13th, 2026, as investors grappled with a complex mix of escalating geopolitical tensions in the Middle East, surging energy prices, and a wave of disappointing corporate guidance. Following a brutal Thursday session that saw the major averages hit their lowest levels of the year, Friday’s trading began with a modest attempt at a relief rally before selling pressure resumed in the afternoon.Major Market Indexes PerformanceAs of the mid-afternoon ...

Eli Lilly and Co (NYSE:LLY) on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitamin B12.The company said internal testing detected a previously unidentified impurity formed when the two substances interact.The drugmaker evaluated compounded products marketed in the U.S. that combine tirzepatide with vitamin B12—also referred to as methylcobalamin, hydroxocobalamin, or cyanocobalamin.Laboratory testing revealed significant levels ...

Key Takeaways Eli Lilly's GLP-1 drugs Mounjaro and Zepbound generated $36.5B in 2025, about 56% of total company revenues.Medicare's BALANCE Model will allow Zepbound and Mounjaro coverage under Part D plans starting in 2027.LLY plans a potential 2Q26 U.S. launch of oral GLP-1 drug orforglipron, if approved, to expand obesity access.Eli Lilly (LLY) , a dominant player in the global obesity market, derives most of its revenues from its blockbuster GLP-1 medicines, Mounjaro for type II diabetes (T2D) and Zepb ...

Market Overview - Major averages are experiencing declines, with the Dow dropping over 400 points as traders assess fluctuating oil prices and a significant inflation report [1] - Markets are trading cautiously due to volatile energy prices and ongoing geopolitical tensions in the Middle East [1] Oil Market Dynamics - Oil prices surged above $100 and briefly approached $120 earlier in the week due to fears of shipping disruptions through the Strait of Hormuz, but have since retreated to below $90 following a coordinated release of emergency reserves [2] - The International Energy Agency has agreed to release approximately 400 million barrels from global strategic stockpiles to stabilize energy markets after a supply shock driven by conflict [2] Geopolitical Tensions - U.S. forces have sunk several Iranian ships, including 16 minelayers, near the Strait of Hormuz, while reports of incidents involving bulk carriers have emerged, highlighting the fragility of global energy supply routes [3] - These developments have contributed to unstable risk sentiment in the market [3] Inflation Data - Recent inflation data indicates that consumer prices rose by 0.3% month-over-month and 2.4% year-over-year, both figures aligning with consensus expectations [4] Company News - Nike (NKE) has been upgraded to Overweight at Barclays due to operational progress [7] - JPMorgan upgraded Oracle (ORCL), citing improved risk/reward following a selloff [7] - Optimum Communications (OPTU) has been downgraded to Market Perform at Raymond James [7] - Yext (YEXT) has been downgraded to Neutral at Roth Capital [7] - Wells Fargo has assigned an Underweight rating to Harley-Davidson (HOG), citing excessive risk [7] - MasterCard (MA) has launched a new Crypto Partner Program, collaborating with over 85 companies in the digital asset and payments sectors [7] - Eli Lilly (LLY) plans to invest $3 billion in China over the next decade [7] - Playboy (PLBY) has appointed Phillip Picardi as chief brand officer and editor in chief [7] - Shell (SHEL) has declared force majeure on liquefied natural gas contracts with some clients in Asia due to the ongoing Qatar LNG shutdown [7] - AMD (AMD) CEO Lisa Su is set to meet with Samsung (SSNLF) Chairman Jay Lee to discuss cooperation on securing supplies of high-bandwidth memory for AI chipsets [7]